Tenaya Therapeutics, Inc. (TNYA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$81.3M
Cash & Equivalents
$19.2M
Quarterly Burn Rate
13 mo
Est. Cash Runway
$189M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase2 Readout | — |
| 2026-08-01 | Phase2 Readout | — |
| 2026-08-08 | Phase3 Readout | — |
| 2026-10-01 | Phase2 Readout | — |
| 2026-12-31 | Phase3 Readout | — |
| 2026-12-31 | Phase2 Readout | — |
| 2026-12-31 | Phase3 Readout | — |
| 2026-12-31 | Phase2 Readout | — |
| 2026-12-31 | Phase3 Readout | — |
| 2026-12-31 | Phase2 Readout | — |
| 2027-01-01 | Phase3 Readout | — |
| 2027-01-01 | Phase2 Readout | — |
| 2027-02-28 | Phase2 Readout | — |
| 2027-03-01 | Phase3 Readout | — |
| 2027-03-31 | Phase2 Readout | — |
| 2027-03-31 | Phase3 Readout | — |
| 2027-04-01 | Phase3 Readout | — |
| 2027-06-30 | Phase3 Readout | — |
Active Clinical Trials (50)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT03516942 | Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment | OTHER | Active Not Recruiting | 565 |
| NCT01806129 | Reproductive Health Program in Patients With Cancer | OTHER | Active Not Recruiting | 434 |
| NCT06112613 | Mobile Health for Adherence in Breast Cancer Patients | OTHER | Recruiting | 410 |
| NCT06002828 | Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors | OTHER | Recruiting | 2,000 |
| NCT05568472 | Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study | OTHER | Active Not Recruiting | 565 |
| NCT06295367 | Cost Communication and Financial Navigation in Cancer Patients (COSTCOM) | OTHER | Recruiting | 760 |
| NCT04579224 | Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothel... | PHASE3 | Active Not Recruiting | 184 |
| NCT01886872 | Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Pr... | PHASE3 | Active Not Recruiting | 547 |
| NCT01169337 | Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma | PHASE3 | Active Not Recruiting | 226 |
| NCT03414970 | Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Canc... | PHASE3 | Active Not Recruiting | 898 |
| NCT03244384 | Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urotheli... | PHASE3 | Active Not Recruiting | 739 |
| NCT03701282 | Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leu... | PHASE3 | Active Not Recruiting | 720 |
| NCT03996265 | Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors | PHASE3 | Active Not Recruiting | 422 |
| NCT01349881 | S0820, Adenoma and Second Primary Prevention Trial | PHASE3 | Active Not Recruiting | 354 |
| NCT02193282 | Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Remo... | PHASE3 | Active Not Recruiting | 390 |
| NCT03150693 | Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leu... | PHASE3 | Recruiting | 303 |
| NCT03851445 | Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | PHASE3 | Recruiting | 10,000 |
| NCT01953588 | Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | PHASE3 | Active Not Recruiting | 1,473 |
| NCT02839707 | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent O... | PHASE3 | Active Not Recruiting | 444 |
| NCT03067181 | Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ C... | PHASE3 | Recruiting | 1,780 |
| NCT01901094 | Comparison of Axillary Lymph Node Dissection with Axillary Radiation for Patients with Node-Positive Breast Cancer Treat... | PHASE3 | Active Not Recruiting | 2,012 |
| NCT02339571 | A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma | PHASE3 | Active Not Recruiting | 600 |
| NCT04248452 | Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Canc... | PHASE3 | Active Not Recruiting | 314 |
| NCT03233711 | Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer | PHASE3 | Active Not Recruiting | 344 |
| NCT04444921 | EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients | PHASE3 | Active Not Recruiting | 205 |
| NCT07369011 | A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight | PHASE3 | Recruiting | 800 |
| NCT01575548 | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery | PHASE3 | Active Not Recruiting | 129 |
| NCT04510597 | Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Me... | PHASE3 | Recruiting | 364 |
| NCT01863550 | Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | PHASE3 | Active Not Recruiting | 1,087 |
| NCT04457596 | T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cance... | PHASE3 | Active Not Recruiting | 1,056 |
| NCT02048813 | Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With U... | PHASE3 | Active Not Recruiting | 529 |
| NCT03811015 | Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer | PHASE3 | Active Not Recruiting | 636 |
| NCT05929768 | Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | PHASE3 | Recruiting | 2,400 |
| NCT04094688 | Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer | PHASE3 | Active Not Recruiting | 455 |
| NCT02785952 | Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squam... | PHASE3 | Active Not Recruiting | 275 |
| NCT05879926 | Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal... | PHASE3 | Recruiting | 3,960 |
| NCT00588770 | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell C... | PHASE3 | Active Not Recruiting | 403 |
| NCT03712605 | Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial | PHASE3 | Active Not Recruiting | 280 |
| NCT04092283 | Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemora... | PHASE3 | Active Not Recruiting | 660 |
| NCT02595944 | Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIS... | PHASE3 | Active Not Recruiting | 903 |
| NCT03375320 | Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | PHASE3 | Active Not Recruiting | 298 |
| NCT02912559 | Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA... | PHASE3 | Active Not Recruiting | 712 |
| NCT02224781 | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Tr... | PHASE3 | Active Not Recruiting | 267 |
| NCT01274338 | Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Remov... | PHASE3 | Active Not Recruiting | 1,673 |
| NCT02201992 | Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK F... | PHASE3 | Active Not Recruiting | 166 |
| NCT03937635 | Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | PHASE3 | Recruiting | 288 |
| NCT04068103 | Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery | PHASE3 | Active Not Recruiting | 635 |
| NCT03737981 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untre... | PHASE3 | Active Not Recruiting | 465 |
| NCT03793166 | Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advan... | PHASE3 | Active Not Recruiting | 1,175 |
| NCT04137107 | Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer | PHASE3 | Active Not Recruiting | 220 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.